Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590633 | 0.90 | MAPT (0.47) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL14228565 | 0.90 | MAPT (0.47) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL3197116 | 0.89 | MAPT (0.46) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL16244706 | 0.89 | HTT (0.46) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL3185946 | 0.89 | MAPT (0.46) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL19590636 | 0.86 | MAPT (0.54) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL17896326 | 0.84 | MAP4K4 (0.46) | MAPTHRH3SIGMAR1SMN1; SMN2NCF1 | |
| SCHEMBL270611 | 0.83 | NCF1 (0.60) | HRH3SIGMAR1SMN1; SMN2NCF1HTT | |
| SCHEMBL14200264 | 0.83 | ALDH1A1 (0.59) | MAPTHRH3SIGMAR1NCF1KCNH2 | |
| SCHEMBL270530 | 0.82 | SIGMAR1 (0.67) | MAPTHRH3SIGMAR1SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | MAPT 4669/4885HRH3 782/4885SIGMAR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.